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SPECT license.Introduction: Dominant cancer foci within the prostate are associated with sites of local recurrence post
radiotherapy. In this systematic review we sought to address the question: ‘‘what is the clinical evidence
to support differential boosting to an imaging deﬁned GTV volume within the prostate when delivered by
external beam or brachytherapy’’.
Materials and methods: A systematic review was conducted to identify clinical series reporting the use
of radiation boosts to imaging deﬁned GTVs.
Results: Thirteen papers describing 11 unique patient series and 833 patients in total were identiﬁed.
Methods and details of GTV deﬁnition and treatment varied substantially between series. GTV boosts
were on average 8 Gy (range 3–35 Gy) for external beam, or 150% for brachytherapy (range 130–155%)
and GTV volumes were small (<10 ml). Reported toxicity rates were low and may reﬂect the modest boost
doses, small volumes and conservative DVH constraints employed in most studies. Variability in patient
populations, study methodologies and outcomes reporting precluded conclusions regarding efﬁcacy.
Conclusions: Despite a large cohort of patients treated differential boosts to imaging deﬁned intra-pros-
tatic targets, conclusions regarding optimal techniques and/or efﬁcacy of this approach are elusive, and
this approach cannot be considered standard of care. There is a need to build consensus and evidence.
Ongoing prospective randomized trials are underway and will help to better deﬁne the role of differential
prostate boosts based on imaging deﬁned GTVs.
 2013 Elsevier Ireland Ltd. Radiotherapy and Oncology 107 (2013) 274–281Open access under CC BY-NC-NDProstate cancer is a multi-focal disease and conventional thera-
pies address this by treating the whole gland. In the case of radia-
tion, such an approach however, may be limiting to the efﬁcacy of
radiotherapy as escalation of dose to improve tumor control may
be limited by adjacent organ at risk tolerance [1].
Whole mount prostate pathology studies suggest in many cases a
dominant cancer focus exists within the gland and may be a driver
of the aggressiveness of the cancer and the epicenter of recurrence
post treatment [2,3]. Thus strategies to identify and intensify treat-
ment to dominant prostate foci (Gross Tumor Volume/GTV) are un-
der active investigation. Advances in Positron Emission
Tomography (PET), Single Positron Emission Tomography (SPECT)
and magnetic resonance imaging (MRI) show promise in identify-
ing prostate GTVs and advances in precision radiotherapy enable
dose intensiﬁcation [4–8]. In this systematic review we sought to
address the question: ‘‘is there clinical evidence to support differ-
ential boosting to an imaging deﬁned GTV boost within the pros-tate when delivered by external beam or brachytherapy (low
dose or high dose rate)’’. In particular we were interested in tech-
niques used for GTV deﬁnition on imaging for boosting and clinical
endpoints of toxicity (both acute and late) and efﬁcacy (biochem-
ical and clinical control) among men so treated.
Materials and methods
Formulation of the research question, search strategy and data
extraction elements were agreed upon by the lead authors (GB,CM)
in advance of the literature review. A search of the PubMed data-
base for the years January 1, 2000–June 30, 2012 was conducted
using the following search strategy ‘‘(intraprostatic[tw] OR intra-
prostatic[tw] OR DIL[tw] OR ipl[tw]) AND (radiation[tw] OR radio-
therapy[tw] OR brachytherapy[tw]) AND prostate[tw]’’. Papers
describing focal salvage treatment (e.g. Nguyen [9] image guidance
for whole gland therapy (e.g. Menard [10]) or partial gland therapy
based on anatomically deﬁned (not lesion deﬁned) targets (e.g.
Nguyen [11]) or where a focal boost was based exclusively on
biopsy results (e.g. Gaudet [12]) rather than lesion imaging were
excluded. Papers included needed to available as full published
manuscripts, available in English and reporting at least one clinical
Fig. 1. PRISMA diagram of systematic review results.
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reporting planning studies without actual patient treatment and
single case reports were not included), Full text versions of the eli-
gible papers were retrieved and reviewed including manual
searching of the bibliographies for other applicable papers. In the
case of one paper [13] the corresponding author was contacted
for additional information regarding clinical outcomes and this
lead to the identiﬁcation of a companion paper [14] with this infor-
mation. For the review, data extracted for each series included year
of report, number of patients treated, proportion of low, intermedi-
ate and high risk patients (NCCN criteria) included in the series,
median PSA among the patient population, methods used for
GTV imaging and GTV delineation criteria, PTV1 delineation crite-
ria, boost technique used and dose of the boost, use of supplemen-
tary pelvic nodal or androgen deprivation therapy, acute and late
toxicity observed (along with toxicity scale used) clinical outcomes
(clinical and/or biochemical control) and series speciﬁc observa-
tions were extracted. Nomenclature regarding intra-prostatic le-
sion deﬁnition differed signiﬁcantly between patient series; for
the purposes of this systematic review, GTV refers to imaging de-
ﬁned intra-prostatic lesions; PTV1 refers to the volumetric expan-
sion on the GTV for the boost and PTV2 refers to the volumetric
expansion of the whole prostate volume to account for setup and
delivery uncertainty. Initial data extraction was undertaken by
one author (GB) with review by a second author (CM). The remain-
ing authors (MH, UVH) contributed to the analysis and interpreta-
tion of the extracted results and the manuscript. Given the
heterogeneous nature of the patient series reported, no formal at-
tempt at a quantitation of bias or analysis of pooled results was at-
tempted however qualitative appraisal of the relative strengths
and weaknesses of the individual series was made and qualitative
statements are included in the results and discussion of the papers.
The primary outcomes of interest were safety (toxicity reported),
efﬁcacy (clinical and biochemical control) as well as method of
lesion delineation.Results
In total, thirteen papers describing eleven unique patient ser-
ies with a total of 833 patients were identiﬁed for data extrac-
tion. A ﬂow diagram of the search results is available in Fig. 1.
As outlined in Table 1, the analyzed literature [13–25] included
patients treated with external beam (EBXRT) focal boost (n = 5
with simultaneous boost; n = 1 with sequential boost) as well
as low dose rate brachytherapy (LDR, n = 4) and high dose rate
brachytherapy (HDR, n = 1). Heterogeneity between the series re-
stricted analyses to qualitative descriptions and pooling of re-
sults of data was not possible. The majority of series were
prospective series examining relatively small numbers of pa-
tients. The largest external beam series (Fontenye et al. [24–
26]) was limited by its retrospective nature and lack of an MRI
panel conﬁrming to current standards [4]. The largest brachy-
therapy series (Ellis et al. [27]) utilized an imaging modality
with recognized technical challenges in interpretation and lim-
ited histopathologic validation. Approximately one quarter of
the patients described met the NCCN criteria [28] for low risk.
Androgen deprivation therapy varied among series as did the
use of nodal radiation. Techniques for GTV deﬁnition used Stan-
dard Uptake Value (SUV) thresholds on 111In-Capromab SPECT
(n = 2) or 18F-Fluorocholine PET imaging (n = 1). MRI based series
(8) generally used a 1.5T magnet with endorectal (ERC) and pel-
vic coils. The T2W sequence was most commonly used
(GTV = decreased intensity with a mass like appearance) with
Dynamic Contrast Enhanced (DCE, GTV = increased enhance-
ment); Diffusion Weighted derived apparent diffusion coefﬁcientmaps (DWI/ADC, GTV = regions of decreased ADC values) or
magnetic resonance spectroscopy (MRSI, GTV = increased cho-
line + creatinine:citrate ratio) used less often. Only one series
[25] utilized T2W + DWI + DCE which reﬂects the current con-
sensus guidelines for prostate imaging [26,29]. Imaging deﬁned
GTVs were transferred to planning images (Computed Tomogra-
phy/CT or Ultrasound/US) through image registration (n = 6) or
manual transfer/’’cognitive fusion’’ (n = 5). Where reported, GTV
volumes ranged from 3.5–6.8 ml; multiple GTVs were deﬁned
in 10% of patients and close GTV proximity (<3–5 mm) to Organs
at Risk (OAR) was noted. Most series deﬁned a PTV1 (most com-
monly 3–4 mm, excluding OAR) for the GTV. For EBXRT series,
PTV2 doses ranged from 64–78 Gy; PTV1 doses from 80–
94.5 Gy. The average differential dose (PTV2–PTV1) was 8 Gy
(BED2, a/b = 3 Gy, range 3–35 Gy). The most common EBXRT rec-
tal dose constraints was V70 <15–30% with rectal Dmax of 76–
80 Gy; bladder constraints were V70 <15–30% and Dmax of
80 Gy. For the brachytherapy series, 125I LDR was most com-
monly used with a PTV2 dose of 145 Gy, a PTV1 dose of
217 Gy (150%) and Dmax to urethra of <130–150%. Median fol-
low-up ranged from 3–66 months. Outcomes reported included
biochemical control in 4 series and toxicity in 10. Grade 4 toxic-
ity was reported in 4 patients (3 rectovesical ﬁstula, 1 hematu-
ria) [17,20,23]. The series with the highest boost differentials
[22,23] included 66 patients with reported late Grade 3 or
greater toxicities that ranged from 0 to 10% including one
patient with ﬁstula formation.Discussion
Histopathologic studies and patterns of recurrence after exter-
nal beam radiotherapy suggest that many men may have a dom-
inant focus of disease in the prostate that is a key driver of cancer
biology and treatment success [2,30]. Evolution of prostate cancer
imaging [4–6] and radiation treatment [7] has driven the explora-
tion of focal intra-prostatic dose escalation. Consensus statements
and prospective trials regarding the implementation of therapies
based on the identiﬁcation of focal intra-prostatic lesions are
emerging [31–33]. Concerns regarding therapies addressing the
focal lesion only are the difﬁculty in identifying men with truly
focal disease [2] and the high risk of recurrence noted to date
when less than whole gland treatment is attempted based on
Fig. 2. An example of the dose distribution of a patient enrolled on the FLAME randomized controlled trial. Left- A standard dose of 77 Gy in 35 fractions is delivered to the
prostate and seminal vesicles. Right- An illustration of an integrated boost of 95 Gy delivered to the GTV with compromised posterior coverage adjacent to the rectum.
276 Boosting imaging deﬁned prostatic tumorsstrategies without explicit lesion targeting [11,34]. For this rea-
son, differential boosting of the prostate with dose escalation to
imaging deﬁned intra-prostatic GTV volumes is attractive. In this
systematic review, a variety of approaches attempting to exploit
this strategy were identiﬁed. The variability in approaches reﬂects
the lack of consensus around key issues that need to be addressed
in order to rigorously assess the efﬁcacy and safety of this
approach.Optimal intra-prostatic GTV boost dose
There have been numerous studies modeling the beneﬁt and
safety of incorporating a boost of dominant intra-prostatic GTV(s)
with whole prostate treatment (see Supplementary References)
and an example is illustrated in Fig. 2. The majority of studies mod-
eling GTV boosts used MRI for GTV delineation with fewer using
PET or SPECT. Anatomy dependence is noted with boosts more
achievable if GTVs are located more than 3 mm from OAR. Like
the clinical data reported here, modeling studies suffer from lack
of consistent methodology for GTV delineation and deformable
mapping onto planning images. The series by Huisman and Van
Lin are notable in that they describe planning workﬂow in detail
and use intra-prostatic ﬁducial markers to assist in image fusion
as well as image guidance for treatment [35,36]. In general, plan-
ning studies suggest that GTV dose escalation up to 95 Gy with
external beam radiotherapy should be feasible for most patients
with a resulting absolute increase in TCP of 2–15%. The ideal GTV
dose remains to be determined however and higher doses that re-
spect OAR tolerances may be difﬁcult to achieve for all patients
depending on the anatomic location of the dominant lesion and
plateaus in TCP beyond doses of 84–90 Gy have been suggested
[37,38]. Achieving a high boost dose at the expense of a lower
(<70–75 Gy) whole prostate dose may be a counter-productive
strategy as increased intraprostatic recurrences have been noted
with this approach [11,34,49]. For example, D’Amico reported on
a series of patients where MRI was used to deﬁne the peripheral
zone as an ‘‘anatomic’’ GTV for dose escalated partial prostate
brachytherapy and noted relatively high failure rates compared
to whole gland brachytherapy series [11]. Clinically, both Schick
and Miralbell [22,23] described series using relatively low
(60 Gy) whole gland treatment with external beam radiotherapy
followed by an intra-prostatic boost with HDR or stereotactic
external beam boost. In both cases, boost volumes were generous
and encompassed the majority of the gland (typically a horseshoe
shaped boost with urethral sparing) which may have contributed
to the relatively favorable control rates seen (78% and 98% 5 year
bDFS respectively).Standards for GTV delineation
The potential beneﬁts of intra-prostatic boosts are dependent
on the performance of the imaging techniques used for GTV delin-
eation [40]. Within the series reviewed imaging used for GTV def-
inition including single parameter MRI, multi-parametric MRI,
SPECT and PET imaging. Of these imaging modalities, MRI has the
strongest evidence base validating MRI against pathology gold
standards (see Supplementary References) but even then consider-
able variability in methodology between these reports exist. Most
MRI validation studies used 1.5T with pelvic and ERCs and evalu-
ated mainly intermediate and high risk patients. T2W was rou-
tinely used with variable incorporation of other sequences (DCE,
DWI, and MRSI). Criteria for lesion identiﬁcation differed consider-
ably between series with some series using qualitative ‘‘suspicion
scales’’ to score sectors or regions ‘‘benign’’ to ‘‘deﬁnitely malig-
nant’’ based on combinations of imaging traits to more quantita-
tive measures based on perfusion or spectroscopy parameters. In
general, test performance (as measured by sensitivity/speciﬁcity
or ROC analysis) is worst for single sequence MRI (performance
around 0.6–0.7) with performance improving for multi-parametric
MRI (performance 0.8–0.9) and this is reﬂected in current consen-
sus guidelines recommending T2W + DWI + DCE for lesion detec-
tion [26,29]. As an example, Futterer [41] reported on 34
patients, intermediate risk, imaged with 1.5T, T2W, DCE and MRSI
and noted that a multi-parametric score of MPKS (mean score of
DCE parameters) + spectroscopy provided the best performance
(ROC Az = 0.94). There is less information regarding performance
of MRI in deﬁning boundaries of lesions compared with pathology
(as opposed to identifying the presence of cancer on a quadrant or
sextant basis). Variations in malignant gland density and sparse tu-
mor distribution can affect visibility of prostate cancer with MRI
and confound lesion delineation [42]. Where reported, modest
concordance levels lesion boundaries on imaging and pathology
are noted (0.6–0.7) with expansions of imaging boundaries by 2–
5 mm to account for imaging and registration uncertainties
improving concordance indices [43–46]. Probability maps gener-
ated by statistical models have demonstrated excellent concor-
dance with pathology deﬁned GTVs in the peripheral zone
[44,47,48] and could be incorporated into radiation ‘‘dose painting’’
treatment planning [49] but still require validation in larger pa-
tient cohorts and across institutions. Finally, biopsy conﬁrmation
of suspicious targets identiﬁed on imaging may be considered in
order to exclude a subset of patients with false-positive imaging
ﬁndings [25]. Such image guided biopsies may address the uncer-
tainty associated with the planning of boost therapies based on
random systematic biopsies of the prostate alone [12] by allowing
precision localization of involved biopsies while avoiding the cost
Table 1
Literature summary.
Reference Patient population Tumor volume delineation Treatment Outcomes
Ippolito Ref. [19] N = 40
Median PSA: 7
1.5 TMRI + ERC; sequences not speciﬁed; fusion; GTV ‘deﬁned on MRI,
consistent with biopsy ﬁndings’
5 ﬁeld IMRT; 6MV Survival
No biochemical failures
LR: 4
IR: 17
HR: 19
PTV2 = prostate + SV + 1 cm
PTV1 = GTV + 5 mm
PTV2: 72 Gy
PTV1: 80 Gy (84 Gy
a/b = 3)
GI toxicity (RTOG/EORTC)
Acute: 15% Grade 2; 5% Grade 3
Late: 5% Grade 2; 2.5% Grade 3
Prospective
feasibility
study; IRB
approved
Median follow-up
19 months
Median PTV1 volume 55 ml Additional treatments
100% ADT
GU toxicity (RTOG/EORTC)
Acute: 30% Grade 2; 2.5% Grade 3
Late: 5% Grade 2; 2.5% (1/40) Grade 4
2 year actuarial risk of toxicity >Grade 2 was 13% (GU); 9.5% (GI)
Pinkawa Ref.
[13,14]
N = 66
Median PSA: 14
LR: 23
IR: 21
HR: 22
18F-Fluorocholine PET; fusion; GTV SUV >2 times background 5 ﬁeld, 15 MV IMRT Survival
NR
Prospective
quality of life
study; IRB not
speciﬁed
Median follow-up
19 months
PTV2 = prostate + SV + 4–8 mm
PTV1 = GTV + 3–4 mm
PTV2 = 76 Gy
PTV1 = 80 Gy (83 Gy
a/b = 3)
GI/GU Toxicity (EPIC)
10% deterioration in brother and function scores at median of 2 months
post radiation; return to baseline by median of 19 months. No difference
between patients who received an SIB (n = 46) vs. no SIB(n = 21)
Extra-prostatic
disease was
detected in 1/66
mean GTV 6.2 ml; 22 had 2 GTV; 7 had 3 GTV deﬁned; 36 GTV had
involvement of central gland; 36 GTV were within 3 mm of rectum;
Additional treatments
16% ADT
Wong Ref. [20]
Prospective
feasibility
study, IRB
approved
N = 71
Median PSA: 6.1
LR: 28
IR: 40
HR: 3
111In-Capromab SPECT; fusion; GTV = SUV 3 muscle SUV 5 ﬁeld IMRT; 6MV Survival
94% 5 year BDFS; 93% 5 year OS (Phoenix)
Median follow-up
66 months
PTV2 = prostate + SV + 6 mm
PTV1 = GTV
PTV2: 75.6 Gy
PTV1: 82 Gy (85 Gy
a/b = 3)
GI Toxicity (Modiﬁed RTOG)
Acute: 45% Grade 2
Late: 15% Grade 2
Median GTV = 7% of PTV2 Additional treatments
60% ADT
GU Toxicity (Modiﬁed RTOG)
Acute: 54% Grade 2; 1% Grade 3
Late: 39% Grade 2; 3% Grade 3; 1% Grade 4
Ellis Ref.
[17,18,27]
N = 239
Median PSA: 7.6
LR: 116
IR: 72
HR: 51
111In-Capromab SPECT gamma contrast uptake ‘‘dialed in’’ to correlate with
biopsy. No fusion
LDR prostate
brachytherapy
Survival
85% 10 year BDFS; 85% OS (Phoenix)
Prospective
study, IRB
approved
111In-Capromab
SPECT suggested
metastatic disease
in 9.2%
PTV2 = prostate + 2–5 mm
PTV1 = GTV + 5 mm
PTV2 = 108–144 Gy
(I125) = 100–125 Gy
(P103)
PTV1 = 150% of PTV2
GI Toxicity (RTOG)
Acute: 4% Grade 2; 0% Grade 3
Late: 2% Grade 2; 1% Grade 4
Median follow-up
NR
Additional treatments
37%: EBXRT
21%: ADT
27%: Node dissection
GU Toxicity
NR
Survival was worse for patients with extra-prostatic disease on SPECT. 2
patients had Grade 4 toxicity (ﬁstula) at 18 and 30 months
Schick Ref. [23] N = 77
Median PSA: NR
LR: 7
IR: 9
HR: 61
A hemi-prostate (n = 20) or bilateral (n = 57) prostate GTV was deﬁned by
correlation of DRE, biopsy results and ERC MRI; if T2W changes and biopsy
involvement conﬁned to same lobe, unilateral boost otherwise bilateral
boost; catheter + 3–5 mm used to deﬁne urethra PRV; no fusion
HDR prostate
brachytherapy
PTV2 = 64.4 Gy
PTV1 = 88–104 Gy
(a/b = 3)
Survival
78% 5 yr BDFS (Phoenix)
Prospective
study; IRB not
speciﬁed
Median follow-up
62–67 months
PTV2 = Prostate + SV
PTV1 = GTV
Patients treated with
an HDR boost after
completing prostate
EBXRT
GI Toxicity (RTOG/EORTC)
Acute: 3% Grade 2; 0% Grade 3/4
Late: 9% Grade 2; 4% Grade 3=4
N = 19: 2  6 Gy GU Toxicity (RTOG/EORTC)
(continued on next page)
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Table 1 (continued)
Reference Patient population Tumor volume delineation Treatment Outcomes
N = 21: 2  7 Gy
N = 37: 2  8 Gy
Additional treatments
81% ADT
36% PLN
Acute: 3% Grade 2; 3% Grade3/4
Late: 10% Grade 2; 9% Grade 3/4
Higher acute and late GU toxicity was noted for bilateral vs. unilateral
boost; one patient (unilateral 2  8 Gy) developed a ﬁstula requiring
pelvic exenteration
Miralbell Ref. [22] N = 50
Median PSA: NR
LR: 5
IR: 12
HR: 33
GTV deﬁned on ERC MRI (T2 + DCE) correlated with biopsy; fusion (ERC used
for planning CT to facilitate); bilateral gland in 48;
3DCRT (n = 39) or IMRT
(n = 11)
PTV2 = 64 Gy
PTV1 = 80–99 Gy
(a/b = 3)
Survival
98% 5 year BDFS (Phoenix)
GI Toxicity(RTOG/EORTC)
Acute: 8% Grade 2; 0% Grade 3
Late: 10% Grade 2; 10% Grade 3
Prospective
study; IRB not
speciﬁed
PTV2 = prostate + SV+?
PTV1 = GTV + 3 mm
stereotactic boost after
completing prostate
EBXRTN = 5: 2  5 Gy
N = 8: 2  6 Gy
N = 8: 2  7 Gy
N = 29: 2  8 Gy
GU Toxicity(RTOG/EORTC)
Acute:46% Grade 2; 4% Grade 3
Late: 12% Grade 2; 0% Grade 3
Additional treatments
56% PLN
66% ADT
No statistically signiﬁcant toxicity difference between high dose arm
(8 Gy  2) vs. lower dose arms; actuarial risk of >Grade 2 toxicity was
18% GU; 28% GI
Fonteyne Ref.
[24]
N = 230
Median PSA: 11.2
LR: 17
IR: 97
HR: 116
GTV deﬁned on 1.5T ERC MRI T2W or MRSI by consensus; 118/230 had MRI
deﬁned GTV; 4/118 were deﬁned on MRSI; 8/118 had more than one GTV
deﬁned. Fusion
3–6 ﬁeld IMRT; daily
U/S guidance
Survival
NR
Retrospective
review; IRB
not speciﬁed
PTV2 = prostate+/ SV + 4 mm
PTV1 = GTV + 8 mm
PTV2: 78 Gy
PTV1: 80 Gy (81 Gy
a/b = 3)
GI Toxicity (modiﬁed RTOG)
Acute: 11% Grade 2; 0% Grade 3
Late: NR
GU Toxicity (modiﬁed RTOG)
Acute: 41% Grade 2; 7% Grade 3
Late: NR
50% had boost to GTV; no difference in toxicity boost vs. no boost
Singh Ref. [25] N = 3 GTV deﬁned on 3T ERC MRI by T2W + DCE + DWI with biopsy conﬁrmation;
gold seed ﬁducials were used for fusion. 1 patient had 2 GTV
IMRT with daily image
guidance
Survival
NR
Prospective,
phase I, IRB
approved
Follow-up of 3–
18 months
PTV2 = prostate + 7 mm
PTV1 = GTV + 3 mm
PTV2 = 75.6 Gy
PTV1 = 94.5 Gy
GI Toxicity (RTOG)
Acute: 0/3 Grade >2
Late: NR
GU Toxicity (RTOG)
Acute: 2/3 Grade 2
Late: NR
First cohort of a Phase I study that seeks to dose escalate the GTV to
152 Gy
DeMeerleer Ref.
[15]
N = 38
Median PSA: 10.2
Three physician consensus read of 1.5T ERCMRI; GTV delineated on T2W (15/
38 patients imaged had GTV deﬁned); median volume was 4 cc; 13/15 were
<5 mm from rectal wall; no fusion
3 Field IMRT Survival
NR
Retrospective
review, IRB not
speciﬁed
LR: 3
IR: 8
HR: 5
PTV2 = prostate + 7–10 mm
PTV1 = GTV + 0 mm
PTV2 = 78 Gy
PTV1 = 80 Gy
GI Toxicity
Acute: 20% Grade 2; 0% Grade 3
Late: NR
GU Toxicity
Acute: 40% Grade 2; 7% Grade 3
Late: NR
Dibase Ref. [16]
Prospective
feasibility, IRB
approved
N = 15
Median PSA: 7.1
1.5T ERC MRI spectroscopy used to manually map voxels with citrate:
choline + creatinine ratio <1.4 onto axial US
LDR prostate
brachytherapy
Survival
NR
LR: 15/15 PTV2 = prostate + 0–2 mm
PTV1 = GTV
PTV2 = 145 Gy (I125)
PTV1 = 188 Gy
GI Toxicity
Acute: ‘‘No rectal morbidity’’
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G. Bauman et al. / Radiotherapy and Oncology 107 (2013) 274–281 279and potential morbidity of intensive biopsy correlations through
template or saturation biopsies either alone or with imaging as
implemented by some investigators for GTV identiﬁcation [32].
There are fewer studies of histopathologic validation of SPECT
and PET. (see Supplemental References) In our review, two large
series with long term follow-up reviewed deﬁned GTVs using
111In Capromab SPECT imaging. Ellis demonstrated a PPV/NPV of
0.68/0.88 using 111In Capromab correlated with biopsy positive
sectors among 7 patients [50]. Mouraviev [51], however, noted
no correlation between 111In Capromab uptake and the presence
of cancer on whole mount pathology in 25 patients. Thus, contin-
ued use of 111In Capromab for GTV delineation would seem ill ad-
vised unless there is further work to validating this imaging against
histopathology. Kwee [52] compared 18F-Fluorocholine PET imag-
ing with whole mount pathology on a sextant basis. They found
SUVmax correlated with sextant involvement and identiﬁed in-
volved sextants with an overall accuracy of 0.72. When comparing
11C-Choline to MRI among 23 patients Vandenbergh [53] noted
11C-Choline had similar performance to T2W with an overall accu-
racy of 0.6–0.7 but PET approached MRI accuracy only for lesions
>0.9 cm3. Like MRI, automated thresholding techniques based on
relative SUV may improve concordance with pathology and can
be exploited for ‘‘dose painting’’ [39,54,55] however the limited
histopathology correlative studies suggest caution in using PET as
the sole modality for GTV deﬁnition.Patient selection and outcomes reporting
In our review of the literature we were able to identify eleven
unique patient series (833 patients) ranging from small prelimin-
ary experiences of 3–4 patients to large institutional series of over
200 patients. The EBXRT series reported were comprised of primar-
ily intermediate to high risk patients; the brachytherapy series in-
cluded a higher proportion of low risk patients. Among all series
there was variability in patient populations, use of androgen depri-
vation (which may affect GTV deﬁnition [56]) use of nodal irradia-
tion, length of follow-up and outcomes reporting that preclude
deﬁnitive statements regarding efﬁcacy of the boost techniques re-
ported to date. While reported toxicity was generally noted to be
low, many (56%) EBXRT patients had a very modest differential
boost of 3 Gy and many of the brachytherapy patients had boosts
which redirected expected ‘‘hot spots’’ into GTV regions. Further-
more, PTV1 coverage was sometimes compromised in order to re-
spect conservative rectal dose constraints. Thus the toxicity proﬁle
noted in this review may not accurately reﬂect risks associated
with more signiﬁcant differential boosts (>10 Gy). It is perhaps
somewhat reassuring that the series with highest boost ranges
did not report dramatically different toxicity than the other series
[22,23]. However, these series used relatively low whole prostate
doses of 64 Gy and generous (hemi prostate or bilateral prostate
GTV) volumes with relatively high HDR or stereotactic dose of 5–
8 Gy  2; complicating extrapolation to other treatment situations.
Efﬁcacy data are limited to reports of biochemical control at early
(5 year) endpoints. No series reported on histopathologic outcomes
(i.e. post treatment biopsies) as an early endpoint and this may be
an opportunity for future clinical trials.Recommendations
Despite a large cohort of patients treated with the use of imag-
ing for delineating and delivering a GTV boost in prostate cancer
conclusions regarding optimal techniques and/or efﬁcacy of this
approach are elusive, and the use of intra-prostatic GTV boost can-
not be considered standard of care. The fact that dominant intra-
prostatic foci appear to be important drivers of cancer outcomes
280 Boosting imaging deﬁned prostatic tumorsjustiﬁes continued exploration of strategies for differential dose
escalation however signiﬁcant issues need to be addressed in order
to rigorously evaluate the validity of this approach. Key issues
identiﬁed through our review include the need for standardized,
reproducible and accurate intra-prostatic GTV deﬁnition guidelines
based on standardized imaging protocols using clinically validated
tools for deformable registration of GTVs onto planning scans. In
this regard PET/CT and SPECT/CT techniques carry the advantage
of potentially simpliﬁed integration into clinical radiation planning
workﬂow but the absence of rigorous histopathology validation of
these modalities argues against these techniques. Multi-paramet-
ric T2W + DCE + DWI has the strongest histopathologic validation
however the fusion of these images with planning CT scans for
GTV deﬁnition is technically more challenging and subject to error
especially when endorectal coil is used for imaging due to gland
deformation. Robust motion management strategies to decrease
the chance of geographic miss of the GTV are required. In this re-
gard use of ﬁducial markers may be a preferred strategy as they
may assist in the image fusion process and also facilitate daily im-
age guidance. Appropriate clinical trial design for evaluating a
strategy of GTV boosting need to be identiﬁed including stratiﬁca-
tion or otherwise controlling for variability in other treatment ele-
ments such as the use of pelvic nodal irradiation, hormone therapy
use and patient selection (low vs. intermediate vs. high risk). Clin-
ical trial endpoints of early and late toxicity are clearly needed
with reporting by standardized toxicity scales (CTCAE or RTOG/
LENT). Traditional clinical endpoints of biochemical control and
disease free survival pose challenges for the efﬁcient evaluation
of new technologies in this disease. Prostate biopsies pre- and at
1–3 years post-treatment directed at both the ‘‘uninvolved’’ pros-
tate as well as the imaging deﬁned GTVs may be an appropriate
surrogate endpoint and have been proposed as primary endpoints
for trials of focal therapy [31]. Such biopsies could help validate
GTV deﬁnition as well as characterize response in both the boosted
and unboosted areas of the prostate although the use of biopsies as
an endpoint needs to consider issues of timing and the challenge of
interpreting histologic response post radiation [57] which may be
more problematic compared to physical ablative therapies such as
high intensity focused ultrasound, cryotherapy or focal laser abla-
tion which produce well deﬁned tissue effects [58]. Other proposed
endpoints to be considered include toxicity and clinical efﬁcacy.
For example, a recent trial of focal therapy based on imaging and
template biopsy targeting used erectile function as a primary end-
point with disease control and biopsy control [32]. Another unre-
solved issue in designing trials is the best technology for GTV
boosting. At this time, both brachytherapy and external beam
boosting strategies appear worthy of investigation. Both LDR and
HDR are inherently inhomogenous in their dose distribution and
‘‘strategic placement’’ of expected hotspots (150%) in the imaging
deﬁned GTV regions should be feasible and reduces the potential
for inter and intra fraction variation in delivery when external
beam techniques are used for GTV boosting. Fusion of pre-treat-
ment imaging with the ultrasound imaging used for brachytherapy
remains a challenge however commercial solutions for MRI-ultra-
sound fusion for needle guidance are becoming available [59]. For
external beam, there are many technologies available that can de-
liver differential boosting and the availability of in-room image
guidance can potentially reduce errors due to inter or intra fraction
motion [60]. An optimal GTV boost dose and fractionation has yet
to be determined for external beam and several lines of investiga-
tion are underway. Current multi-institutional trials of GTV boosts
based on multi-parametric MRI are underway including FLAME
[61] and HEIGHT (clinicialtrials.gov NCT0141132) are evaluating
a GTV boosts equivalent to 95 Gy with whole prostate doses in
the range of 76–77 Gy. A phase II trial (clinicialtrials.gov
NCT01409473) is examining a hypofractionated strategy withwhole prostate doses in the range of 40–45 Gy/5 fractions with
simultaneous boost of the GTV of 50 Gy/5. DELINEATE is a Phase
II study examining the toxicity and feasibility of a dose escalated
boost to magnetic resonance imaging identiﬁed tumor nodule(s)
in localized prostate cancer [http://www.controlled-trials.com/
ISRCTN04483921].Conclusions
Available literature describes patients treated with modest
boosts to intra-prostatic GTVs although standards for imaging,
GTV delineation, treatment planning and dose remain to be deter-
mined and the available clinical series do not permit conclusions
regarding the safety or efﬁcacy of this approach. At the current
time, this approach cannot be considered standard of care. Ongoing
prospective trials are underway and will help to better deﬁne the
role of differential prostate boosts based on imaging deﬁned GTVs.
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